1997
DOI: 10.1210/jcem.82.2.3735
|View full text |Cite
|
Sign up to set email alerts
|

Body Weight, Body Fat Distribution, and Hormonal Replacement Therapy in Early Postmenopausal Women

Abstract: Body weight was measured, and body fat distribution was determined by dual energy x-ray in early postmenopausal women given either oral calcium (500 mg/day; control group; n ϭ 12) or hormonal replacement therapy (HRT), a combination of estradiol valerate (2 mg/day for 21 days) with cyproterone acetate (1 mg/day in the last 10 days of the treatment cycle; n ϭ 15). There were no differences in basal body weight or body fat distribution in the two groups before the study. In the control group, a significant (P Ͻ … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

8
109
3
12

Year Published

1999
1999
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 250 publications
(132 citation statements)
references
References 27 publications
8
109
3
12
Order By: Relevance
“…This phenotype is associated with a greater risk of insulinresistant diabetes, cardiovascular disease, and breast cancer (1). Estrogen insufficiency is thought to be largely responsible for the increase in adiposity during menopause because postmenopausal women who receive estrogen replacement therapy do not display the characteristic abdominal weight gain pattern usually associated with menopause (2). The role that estrogens play in lipid metabolism in the body is also highlighted by the fact that individuals of both sexes with natural mutations of the gene encoding aromatase, the enzyme responsible for estrogen biosynthesis, develop truncal obesity, insulin resistance, hypercholesterolemia, and hypertriglyceridemia (3)(4)(5)(6).…”
mentioning
confidence: 99%
“…This phenotype is associated with a greater risk of insulinresistant diabetes, cardiovascular disease, and breast cancer (1). Estrogen insufficiency is thought to be largely responsible for the increase in adiposity during menopause because postmenopausal women who receive estrogen replacement therapy do not display the characteristic abdominal weight gain pattern usually associated with menopause (2). The role that estrogens play in lipid metabolism in the body is also highlighted by the fact that individuals of both sexes with natural mutations of the gene encoding aromatase, the enzyme responsible for estrogen biosynthesis, develop truncal obesity, insulin resistance, hypercholesterolemia, and hypertriglyceridemia (3)(4)(5)(6).…”
mentioning
confidence: 99%
“…Modifications linked to menopause are believed to be the consequence of gonadal steroid deficiency and counteracted by gonadal steroid supplementation. However, the effects exerted by steroid administration on body weight or fat distribution are rather conflicting (10,12,13,(15)(16)(17)(18)(19)(20), inefficacy of steroid being reported by several investigators (12,13,15,16). Inconsistencies may derive from differences in experimental design, selected population, type of menopause considered, and hormones administered.…”
mentioning
confidence: 99%
“…The menopause transition, as well as the early postmenopausal period, is associated with an increase in total and central obesity (7)(8)(9). Increased visceral fat is associated with insulin resistance (10), and this preferential storage of abdominal fat may contribute to cardiovascular disease and diabetes in postmenopausal women.…”
mentioning
confidence: 99%
“…Increased visceral fat is associated with insulin resistance (10), and this preferential storage of abdominal fat may contribute to cardiovascular disease and diabetes in postmenopausal women. Estrogen and HRT may improve fat distribution in postmenopausal women by preventing the increase in central body fat (7,(11)(12)(13). However, the evidence concerning the effects of HRT on glucose homeostasis is controversial.…”
mentioning
confidence: 99%